Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease

Recruiting 20 enrolled Institute of Hematology & Blood Diseases Hospital, China

NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, single-arm, multicenter, open-label study to evaluate the efficacy and safety of aponermin-based bridging therapy prior to CAR-T infusion in relapsed/refractory multiple myeloma patients with extramedullary disease.

Timeline

Start: 2025-04-09
Primary completion: 2026-06
Completion: 2026-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Apornemin	Unknown	10 mg/kg	Intravenous
Background	Carfilzomib	Other / unclassified	27 mg/m2	Intravenous
Background	Dexamethasone	Small molecule	20 mg	Intravenous
Background	Thalidomide	Other / unclassified	150 mg	Oral
Background	anti-BCMA/GPRC5D bispecific CAR-T	Cell therapy	2e+06 cells/kg	Intravenous
Background	anti-BCMA/GPRC5D bispecific CAR-T	Cell therapy	4e+06 cells/kg	Intravenous

Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease

Summary

Timeline

Drugs

Indications